101 related articles for article (PubMed ID: 12520979)
1. Gleevec: zeroing in on cancer.
Capriotti T
Medsurg Nurs; 2002 Dec; 11(6):301-4. PubMed ID: 12520979
[No Abstract] [Full Text] [Related]
2. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
Woo SM; Huh CH; Park KC; Youn SW
J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
[No Abstract] [Full Text] [Related]
3. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
Mahon FX; Molimard M
Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
[No Abstract] [Full Text] [Related]
4. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
[No Abstract] [Full Text] [Related]
5. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
Cerchione C; Fabbricini R; Pane F; Luciano L
Leuk Res; 2009 Aug; 33(8):e104-5. PubMed ID: 19232719
[No Abstract] [Full Text] [Related]
6. Cutaneous reactions to STI571.
Brouard M; Saurat JH
N Engl J Med; 2001 Aug; 345(8):618-9. PubMed ID: 11529225
[No Abstract] [Full Text] [Related]
7. Clinical pharmacokinetics of imatinib mesylate.
Levêque D; Maloisel F
In Vivo; 2005; 19(1):77-84. PubMed ID: 15796158
[TBL] [Abstract][Full Text] [Related]
8. Imatinib and pregnancy.
Ali R; Ozkalemkas F; Ozcelik T; Ozkocaman V; Ozkan A
J Clin Oncol; 2006 Aug; 24(23):3812-3; author reply 3813. PubMed ID: 16896012
[No Abstract] [Full Text] [Related]
9. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
Breccia M; D'Elia GM; D'Andrea M; Latagliata R; Alimena G
Eur J Haematol; 2005 Jan; 74(1):89-90. PubMed ID: 15613116
[No Abstract] [Full Text] [Related]
10. Peritoneal tuberculosis after imatinib therapy.
Senn L; Kovacsovics T; Tarr PE; Meylan P
Arch Intern Med; 2009 Feb; 169(3):312-3. PubMed ID: 19204223
[No Abstract] [Full Text] [Related]
11. Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
Matsue K; Matsuo K; Fujiwara H; Iwama K; Hayama BY; Kimura S; Yamakura M; Takeuch M
Thromb Haemost; 2009 Jun; 101(6):1170-1. PubMed ID: 19492163
[No Abstract] [Full Text] [Related]
12. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
[No Abstract] [Full Text] [Related]
13. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
[TBL] [Abstract][Full Text] [Related]
14. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
15. FDA approves Gleevec for pediatric leukemia.
FDA Consum; 2003; 37(4):6. PubMed ID: 12971334
[No Abstract] [Full Text] [Related]
16. [Trends in molecular targeting therapeutics for chronic myeloid leukemia].
Nagai T
Rinsho Ketsueki; 2007 Oct; 48(10):1360-9. PubMed ID: 17933121
[No Abstract] [Full Text] [Related]
17. Imatinib mesylate as a cause of acute liver failure.
Cross TJ; Bagot C; Portmann B; Wendon J; Gillett D
Am J Hematol; 2006 Mar; 81(3):189-92. PubMed ID: 16493605
[TBL] [Abstract][Full Text] [Related]
18. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy.
Dib EG; Ifthikharuddin JJ; Scott GA; Partilo SR
Leuk Res; 2005 Feb; 29(2):233-4. PubMed ID: 15607374
[No Abstract] [Full Text] [Related]
19. Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment.
Gambacorti-Passerini C; Piazza R; Tornaghi L; Pilotti S; Pogliani E
J Natl Cancer Inst; 2004 Nov; 96(22):1723-4. PubMed ID: 15547187
[No Abstract] [Full Text] [Related]
20. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
Lazarevic V; Golovleva I; Nygren I; Wahlin A
Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
[No Abstract] [Full Text] [Related]
[Next] [New Search]